IN2015DN00961A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00961A
IN2015DN00961A IN961DEN2015A IN2015DN00961A IN 2015DN00961 A IN2015DN00961 A IN 2015DN00961A IN 961DEN2015 A IN961DEN2015 A IN 961DEN2015A IN 2015DN00961 A IN2015DN00961 A IN 2015DN00961A
Authority
IN
India
Prior art keywords
compounds
composition
methods
general formula
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Luke Green
Haiyan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2015DN00961A publication Critical patent/IN2015DN00961A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
IN961DEN2015 2012-10-29 2013-10-25 IN2015DN00961A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12190319 2012-10-29
PCT/EP2013/072361 WO2014067861A1 (en) 2012-10-29 2013-10-25 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel

Publications (1)

Publication Number Publication Date
IN2015DN00961A true IN2015DN00961A (es) 2015-06-12

Family

ID=47143594

Family Applications (1)

Application Number Title Priority Date Filing Date
IN961DEN2015 IN2015DN00961A (es) 2012-10-29 2013-10-25

Country Status (24)

Country Link
US (1) US9611232B2 (es)
EP (1) EP2912034B1 (es)
JP (1) JP6216385B2 (es)
KR (1) KR20150075091A (es)
CN (1) CN104781256B (es)
AR (1) AR093168A1 (es)
AU (1) AU2013339607A1 (es)
BR (1) BR112015003996A2 (es)
CA (1) CA2879249A1 (es)
CL (1) CL2015000906A1 (es)
CO (1) CO7170170A2 (es)
CR (1) CR20150159A (es)
EA (1) EA026161B1 (es)
HK (1) HK1207632A1 (es)
IL (1) IL237331A0 (es)
IN (1) IN2015DN00961A (es)
MA (1) MA38135B1 (es)
MX (1) MX2015002399A (es)
PE (1) PE20150775A1 (es)
PH (1) PH12015500292A1 (es)
SG (1) SG11201500585XA (es)
TW (1) TW201422596A (es)
UA (1) UA114649C2 (es)
WO (1) WO2014067861A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102047502B1 (ko) * 2016-06-20 2019-11-22 셀라이온바이오메드 주식회사 포타슘 채널 단백질을 이용한 암 진단용 조성물
EP3941903A1 (en) 2019-03-22 2022-01-26 Saniona A/S Novel potassium channel inhibitors
JP2023544520A (ja) 2020-09-22 2023-10-24 サニオナ エー/エス 新規カリウムチャネル阻害剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2538424C2 (de) * 1975-08-29 1983-01-05 Nordmark-Werke Gmbh, 2000 Hamburg 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat
EP0215435B1 (en) * 1985-09-09 1993-03-03 Otsuka Pharmaceutical Co., Ltd. 2-oxa-isocephem compounds, compositions containing same and processes for preparing same
EP0557408A4 (en) * 1990-11-06 1993-10-27 Smith-Kline Beecham Corporation Imidazolidinone compounds
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
AU1812197A (en) * 1996-03-01 1997-09-16 Sankyo Company Limited Hydroxamic acid derivatives
EP1144387A1 (en) * 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
EP1254895B1 (en) * 2000-01-20 2007-05-23 Eisai R&D Management Co., Ltd. Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
JP3966693B2 (ja) * 2000-01-20 2007-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 含窒素環化合物およびそれらを含んでなる医薬組成物
US6903089B1 (en) * 2000-11-22 2005-06-07 Bayer Aktiengesellschaft Lactam-substituted pyrazolopyridine derivatives
US7879839B2 (en) 2004-07-29 2011-02-01 Merck Sharp & Dohme Corp. Potassium channel inhibitors
DE102004060229A1 (de) * 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
US7378530B2 (en) * 2005-02-22 2008-05-27 Nereus Pharmaceuticals, Inc. Anti-cancer and anti-microbial 5-membered heterocyclic compounds
US20100056637A1 (en) 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
WO2007109098A2 (en) * 2006-03-16 2007-09-27 Azevan Pharmaceuticals, Inc. HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS
AR074558A1 (es) * 2008-12-12 2011-01-26 Solvay Pharm Bv Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3
WO2010123997A1 (en) * 2009-04-22 2010-10-28 Achaogen, Inc. Carbacephem beta-lactam antibiotics

Also Published As

Publication number Publication date
US9611232B2 (en) 2017-04-04
TW201422596A (zh) 2014-06-16
PE20150775A1 (es) 2015-05-21
CN104781256B (zh) 2017-09-29
MA38135A2 (fr) 2016-11-30
SG11201500585XA (en) 2015-04-29
HK1207632A1 (en) 2016-02-05
CA2879249A1 (en) 2014-05-08
PH12015500292A1 (en) 2015-04-20
JP6216385B2 (ja) 2017-10-18
IL237331A0 (en) 2015-04-30
BR112015003996A2 (pt) 2017-07-04
MA38135B1 (fr) 2018-11-30
KR20150075091A (ko) 2015-07-02
EA201590729A1 (ru) 2015-07-30
US20150246894A1 (en) 2015-09-03
MX2015002399A (es) 2015-06-10
AR093168A1 (es) 2015-05-20
EA026161B1 (ru) 2017-03-31
CN104781256A (zh) 2015-07-15
AU2013339607A1 (en) 2015-02-05
CO7170170A2 (es) 2015-01-28
EP2912034A1 (en) 2015-09-02
WO2014067861A1 (en) 2014-05-08
UA114649C2 (uk) 2017-07-10
JP2015535231A (ja) 2015-12-10
EP2912034B1 (en) 2017-05-31
CL2015000906A1 (es) 2015-09-11
CR20150159A (es) 2015-04-30

Similar Documents

Publication Publication Date Title
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
PH12015500263A1 (en) New bicyclic derivatives
IN2015DN00127A (es)
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
MY181898A (en) Heterocyclic compounds and uses thereof
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2013002784A (es) Heteroarilos fusionados y sus usos.
MX2012008141A (es) Compuestos y metodos.
IN2014DN09450A (es)
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
WO2013155338A8 (en) Substituted benzamides and their uses
IN2015DN00961A (es)
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
EA201391421A1 (ru) Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана
MX2013013021A (es) Nuevos compuestos de hexahidropirroloimidazolona.
UY33207A (es) Métodos de preparación de tiazolidinas
WO2013013238A3 (en) Compounds and related compositions and methods of use
UA72478U (ru) Применение полентара как средства фригопротекторного действия
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
ES2421810A2 (es) Intermedios utiles para la sintesis de fexofenadina, procedimientos para su preparacion y para la preparacion de fexofenadina
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия
UA52376U (ru) Применение КОРВИТИНА в качестве средства фригопротекторного действия
UA52378U (ru) Применение ЛИПОФЛАВОНА в качестве средства фригопротекторного действия